APA

Kato S., Jardim D. L., Johnson F. M., Subbiah V., Piha-Paul S., Tsimberidou A. M., Falchook G. S., Karp D., Zinner R., Wheler J., Janku F., Fu S., Lim J., Bean S., Nguyen L., Urban S., Browne E., Meric-Bernstam F. & Hong D. S. (20190225). Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. : Investigational new drugs.

Chicago

Kato Shumei, Jardim Denis L, Johnson Faye M, Subbiah Vivek, Piha-Paul Sarina, Tsimberidou Apostolia M, Falchook Gerald S, Karp Daniel, Zinner Ralph, Wheler Jennifer, Janku Filip, Fu Siqing, Lim JoAnn, Bean Stacie, Nguyen Ly, Urban Susan, Browne Elsa, Meric-Bernstam Funda and Hong David S. 20190225. Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. : Investigational new drugs.

Harvard

Kato S., Jardim D. L., Johnson F. M., Subbiah V., Piha-Paul S., Tsimberidou A. M., Falchook G. S., Karp D., Zinner R., Wheler J., Janku F., Fu S., Lim J., Bean S., Nguyen L., Urban S., Browne E., Meric-Bernstam F. and Hong D. S. (20190225). Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. : Investigational new drugs.

MLA

Kato Shumei, Jardim Denis L, Johnson Faye M, Subbiah Vivek, Piha-Paul Sarina, Tsimberidou Apostolia M, Falchook Gerald S, Karp Daniel, Zinner Ralph, Wheler Jennifer, Janku Filip, Fu Siqing, Lim JoAnn, Bean Stacie, Nguyen Ly, Urban Susan, Browne Elsa, Meric-Bernstam Funda and Hong David S. Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. : Investigational new drugs. 20190225.